The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers

International Journal of Antimicrobial Agents

Volumn 15, Issue 4, 2000, Pages 283-289

  Allen, A ^a   Bygate, E ^a   Faessel, H ^a   Isaac, L ^a   Lewis, A ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Clinical Pharmacology Statistics   (United Kingdom)

Author keywords

Drug interactions; Ferrous sulphate; Fluoroquinolone; Gemifloxacin; Pharmacokinetics; Sucralfate

Indexed keywords

FERROUS SULFATE; GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FERROUS COMPOUNDS; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; REFERENCE VALUES; SUCRALFATE;

EID: 0033867094     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00187-4     Document Type: Article

References (36)

1. Oh J.I., Paek K.S., Ahn M.J. et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother. 40:1996;1564-1568.
2. Cormican M.G., Jones R.N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother. 41:1997;204-211.
3. Hohl A.F., Frei R., Pünter V. et al. International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin Microbiol Infect. 4:1998;280-284.
4. Hardy D., Amsterdam D., Mandell L., Rotstein C. Comparative in vitro activity of gemifloxacin, moxifloxacin, trovafloxacin, sparfloxacin, grepafloxacin, ofloxacin, ciprofloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci [Abstract P482]. J Antimicrob Chemother. 44(Suppl A):1999;146.
5. Moore T, Niconovich N, Coleman K. SB-265805 (LB20304a): In Vitro Antibacterial Activity Against the Common Respiratory Tract Pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. San Diego, CA: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998 [Poster F-098].
6. Critchley IA, Broskey J, Coleman K. SB-265805 (LB20304a): In-vitro Activity, Intracellular Accumulation and Killing of Legionella pneumophila in Human Macrophages. San Diego, CA: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998 [Poster F-100].
7. Felmingham D., Robbins M.J., Dencer C., Salman H., Mathias I., Ridgway G.L. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp. [Abstract P408]. J Antimicrob Chemother. 44(Suppl A):1999;131.
8. Naber K.G., Hollauer K., Kirchbauer D., Witte W. In vitro activity of SB-265805 versus gatifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens. Clin Microbiol Infect. 5(Suppl 3):1999;144.
9. Allen A., Bygate E., Teillol-Foo M., Oliver S.D., Johnson M.R., Ward C. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers [Abstract P440]. J Antimicrob Chemother. 44(Suppl A):1999;137.
10. Allen A., Bygate E., Teillol-Foo M., Oliver S.D., Johnson M.R., Ward C. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers [Abstract P418]. J Antimicrob Chemother. 44(Suppl A):1999;133.
11. Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet. 2:1977;269-280.
12. Jaehde U., Sörgel F., Koch H.U., Stephan U., Gottschalk B., Schunack W. Gastrointestinal and hepatic drug interactions with perfloxacin, a new quinolone. Clin Pharmacol Ther. 41:1987;166.
13. Höffken G., Lode H., Wiley R. et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis. 10(Suppl 1):1988;S138-139.
14. Teng R., Dogolo L.C., Willavize S.A., Friedman H.L., Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 39(Suppl B):1997;93-97.
15. Parpia S.H., Nix D.E., Hejmanowski L.G., Goldstein H.R., Wilton J.H., Schentag J.J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother. 33:1989;99-102.
16. Grasela T.H., Schentag J.J., Sedman A.J. et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 33:1989;615-617.
17. Granneman G.R., Stephan U., Birner B., Sörgel F., Mukherjee D. Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet. 22(Suppl 1):1992;83-89.
18. Garrelts J.C., Godley P.J., Peterie J.D., Gerlach E.H., Yashke C.C. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 34:1990;931-933.
19. Shiba K., Sakai O., Shimada J., Okazaki O., Aoki H., Hakusui H. Effect of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 36:1992;2270-2274.
20. Lehto P., Kivistö K.I., Neuvonen P.J. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol. 37:1994;82-85.
21. Lomaestro B.M., Bailie G.R. Quinolone-cation interactions: a review. Ann Pharmacother. 25:1991;1249-1258.
22. Chiou W.L. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 6:1978;539-547.
23. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 50:1995;1096-1121.
24. Brouwers J.R.B.R. Drug interactions with quinolone antibacterials. Drug Saf. 7:1992;268-281.
25. Deppermann K.-M., Lode H. Fluoroquinolones: interaction profile during enteral absorption. Drugs. 45(Suppl 3):1993;65-72.
26. Spivey J.M., Cummings D.M., Pierson N.R. Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy. 16:1996;314-316.
27. Brouwers J.R.B., Van der Kam H.J., Sijtsma J., Proost J.H. Important reduction of ciprofloxacin absorption by sucralfate and magnesium citrate solution. Drug Invest. 2:1990;197-199.
28. Shiba K, Yoshida M, Kachi M et al. Effects of Peptic Ulcer Healing Drugs on the Pharmacokinetics of a New Quinolone Ofloxacin. Berlin: 17th International Congress of Chemotherapy, 1991 [Abstract 415].
29. Ryerson B, Toothaker R, Schleyer R, Sedman A, Colburn W. Effect of Sucralfate on Enoxacin Pharmacokinetics. Houston, TX: Proceedings of the 29th Interscience Conference on Antimicrobial agents and Chemotherapy, 1989 [Abstract 214].
30. Zix J.A., Geerdes-Fenge H.F., Rau M. et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother. 41:1997;1668-1672.
31. Stass H, Schüly U, Wandel C, Möller J-G, Delesen H. Study to Evaluate the Interaction Between Oral Moxifloxacin and Sucralfate in Healthy Volunteers. San Francisco, CA: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999 [Abstract 7].
32. Van Slooten A.D., Nix D.E., Wilton J.H., Love J.H., Spivey J.M., Goldstein H.R. Combined use of ciprofloxacin and sucralfate. Ann Pharmacother. 25:1991;578-581.
33. Lee L.-J., Hafkin B., Lee I.-D., Hoh J., Dix R. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 41:1997;2196-2200.
34. Allen A., Vousden M., Lewis A. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy. 45:1999;496-503.
35. Davy M., Allen A., Bird N., Rost K.L., Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy. 45:1999;478-484.
36. Allen A., Vousden M., Porter A., Lewis A. Effect of Maalox® on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 45:1999;504-511.